Xpress Biologics

Liege, Belgium Founded: 2014 • Age: 12 yrs Acquired By Polyplus Transfection
CRO offering recombinant protein and antibody related services for preclinical and clinical applications

About Xpress Biologics

Xpress Biologics is a Healthcare company based in Liege (Belgium) founded in 2014, and was acquired by Polyplus Transfection in December 2022. CRO offering recombinant protein and antibody related services for preclinical and clinical applications. The company has 51 employees. Xpress Biologics offers products and services including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools. Its focus areas include Biopharma Outsourcing, CDMO and Biologics.

Company details

Xpress biologics is a contract research organisation offering services in the following areas designing of protein purification system (bacteria and yeasts), process development and manufacturing of new biologics (recombinant proteins, antibody fragments, and plasmid DNA), biosimilars and biobetters, and the management of the pre-clinical and clinical trials management of the GMP manufacturing. The company provides these services to human and veterinary healthcare markets and diagnostic markets. Additionally, the company also provides services in analytical testing.

  • Headquarters Liege, Belgium
  • Employees 51
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website xpress-biologics.com/en
  • Social LinkedIn
  • Acquired by Polyplus Transfection (Dec 2022)
  • Legal Name Xpress Biologics
Key Metrics

Products & Services of Xpress Biologics

Xpress Biologics offers a comprehensive portfolio of products and services, including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.

Recombinant Protein Manufacturing
Production Service

Develops and produces recombinant proteins for research and clinical use.

Plasmid DNA Manufacturing
Manufacturing Service

Produces plasmid DNA for vaccine and therapeutic applications.

Antibody Fragment Manufacturing
Biotech Service

Manufactures antibody fragments for diagnostics and treatments.

Development of Analytical Tools
Analytical Service

Creates tools for quality control in biologics production.

Investors in Xpress Biologics

Xpress Biologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Polyplus Transfection and ARCHIMED.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Healthcare industries are funded and supported globally by ARCHIMED.
archimed.groupLyon, France
Transfection Solutions for Healthcare and Life Sciences organizations
2001polyplus-transfection.comIllkirch Graffenstaden, France
Premium access

Investor details for Xpress Biologics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Xpress Biologics

3 dated milestones of Xpress Biologics across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Xpress Biologics is founded.
  2. Exit Acquired by ARCHIMED.
  3. Exit Acquired by Polyplus Transfection.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Xpress Biologics

Premium access

Complete news archive for Xpress Biologics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Xpress Biologics

Xpress Biologics was founded in 2014.

Xpress Biologics is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.

Xpress Biologics has 51 employees.

Xpress biologics is a contract research organisation offering services in the following areas designing of protein purification system (bacteria and yeasts), process development and manufacturing of new biologics (recombinant proteins, antibody fragments, and plasmid DNA), biosimilars and biobetters, and the management of the pre-clinical and clinical trials management of the GMP manufacturing. The company provides these services to human and veterinary healthcare markets and diagnostic markets. Additionally, the company also provides services in analytical testing.

Xpress Biologics offers Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.

Xpress Biologics has 2 investors. Key investors include Polyplus Transfection, and ARCHIMED.

Xpress Biologics operates through Xpress Biologics.

Yes. Xpress Biologics was acquired by Polyplus Transfection in December 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available